ATUM

History

Year	Detail
2003	Atum (earlier known as DNA2.0) is a biotechnology company founded by Claes Gustafsson, Ph.D., Jeremy Minshull, Ph.D., Sridhar Govindarajan, Ph.D., and Jon Ness, Ph.D. ATUM's headquarters are in Newark, California.
2012	The company collaborated with Aldevron to improve recombinant protein production in insect cell culture.
2012	The company collaborated with the Gene Therapy Program at the Perelman School of Medicine, University of Pennsylvania, to evaluate the impact of gene optimization on in vivo protein expression.
2012	The company partnered with Newcastle University to develop a protein expression system for Bacillus subtillis.
2012	DNA2.0 collaborated with VTU Technology, a provider of Pichia pastoris protein expression services, to develop and refine a gene design algorithm that enabled maximized protein production in the yeast P. pastoris.
2013	The company collaborated with the Infection and Immunity Research Centre at St. George’s, University of London, to support the development of plant-based biopharmaceuticals.
2015	The United States Patent and Trade Office issued U.S. Patent No. 8,975,042, covering the unique technology created by DNA2.0 scientists for synthetic fluorescent and colored proteins and the methods for using them.
2016	The company acquired all of the assets of MIGS LLC, based in Lebanon. MIGS LLC is an NH-based integrated contract research organization specializing in humanization and the production of antibodies and antibody-like molecules that support preclinical studies with microgram-to-gram quantities of protein.
2018	The company collaborated with Just Biotherapeutics to access the company’s Leap-In cell line development tools.
2019	Solentim, a provider of cell line development instrumentation, collaborated with the company to enable rapid, high-expression, stable cell line development by integrating Solentim’s VIPS (verified in-situ plate seeding) hardware for isolating single cells with ATUM’s efficient Leap-In Transposase expression technology.
2020	ATUM and Phylex BioSciences collaborated to accelerate the development of a universal SARS coronavirus vaccine.
2022	The company partners with TrioBio to deliver leap-in transposase-based bioengineering solutions to the Chinese pharmaceutical market.
2023	The company partners with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases to develop orally delivered enzyme therapies for malabsorption and nutrient metabolism disorders.
2024	The company launched the CHO-K1-based discoCHOTM cell line for transient protein production.